Browsing by Author "Lara Hernández, Bárbara Alejandra"

Now showing 1 - 6 of 6
  • Thumbnail Image
    Item
    Alteración de signos vitales dentro de las 72 h previas a la activación de código azul en pacientes adultos hospitalizados de un hospital universitario
    (2018) Araos Baeriswyl, Esteban Andrés; Feuerhake, Teo; Mundaca, Manuel; Lara Hernández, Bárbara Alejandra; Ortega, Francisco; Aeschlimann del Río, Nicolás Alejandro; Eymin Lago, Gonzalo
  • Thumbnail Image
    Item
    Association Between Pulmonary Embolism and COVID-19 in Emergency Department Patients Undergoing Computed Tomography Pulmonary Angiogram : The PEPCOV International Retrospective Study
    (2020) Freund, Y.; Drogrey, M.; Miro, O.; Marra, A.; Feral-Pierssens, A. L.; Penaloza, A.; Lara Hernández, Bárbara Alejandra; Beaune, S.; Gorlicki, J.; Ayar, P. V.; Truchot, J.; Pena, B.; Aguirre, A.; Femy, F.; Javaud, N.; Chauvin, A.; Chouihed, T.; Montassier, E.; Claret, P. G.; Occelli, C.; Roussel, M.; Brigant, F.; Ellouze, S.; Le Borgne, P.; Laribi, S.; Simon, T.; Lucidarme, O.; Cachanado, M.; Bloom, B.
  • Thumbnail Image
    Item
    Capillary refill time during fluid resuscitation in patients with sepsis-related hyperlactatemia at the emergency department is related to mortality
    (2017) Lara Hernández, Bárbara Alejandra; Enberg, L.; Ortega Gutiérrez, Marcos Eduardo; León, P.; Kripper, Cristóbal; Aguilera Fuenzalida, Pablo René; Kattan Tala, Eduardo José; Castro López, Ricardo; Bakker, Jan; Hernández P., Glenn
  • Thumbnail Image
    Item
    Consultas ambulatorias pediátricas atendidas en el Servicio de Urgencia de un hospital universitario
    (2014) Lara Hernández, Bárbara Alejandra; Aguilera Fuenzalida, Pablo René; Garrido, M.; Hirsch Birn, Tamara Eugenia; Swadron, S.; Saldías Peñafiel, Fernando
  • Thumbnail Image
    Item
    Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial
    (2021) Balcells Marty, Maria Elvira; Rojas Orellana, Luis Esteban; Martínez Valdebenito, Constanza Pamela; Ceballos Valdivielso, María Elena Andrea; Ferrés Garrido, Marcela Viviana; Chang Rathkamp, Mayling Raquel; Vizcaya Altamirano, María Cecilia; Mondaca Contreras, Sebastián Patricio; Huete Garín, Isidro Álvaro; Castro López, Ricardo Adolfo; Sarmiento Maldonado, Mauricio; Villarroel Del Pino, Luis Antonio; Pizarro Ibáñez, Alejandra Valentina; Ross Pérez, Patricio Daniel; Santander Toro, Jaime Andrés; Lara Hernández, Bárbara Alejandra; Ferrada Koch, Marcela Patricia; Vargas Salas, Sergio Sebastián; Beltrán Pávez, Carolina; Soto Rifo, Ricardo; Valiente Echeverria, Fernando Andrés; Caglevic, Christian; Mahave, Mauricio; Selman Bravo, Carolina Antoniett; Gazitúa, Raimundo; Briones, José Luis; Villarroel Espíndola, Franz; Balmaceda Araque, Carlos Felipe; Espinoza Sepúlveda, Manuel Antonio; Pereira Garces, Jaime; Nervi Nattero, Bruno; Le Corre Perez, Monique Nicole
    Background: Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP therapy in COVID-19 progression.", "Methods and findings", "The study was an open-label, single-center randomized clinical trial performed in an academic medical center in Santiago, Chile, from May 10, 2020, to July 18, 2020, with final follow-up until August 17, 2020. The trial included patients hospitalized within the first 7 days of COVID-19 symptom onset, presenting risk factors for illness progression and not on mechanical ventilation. The intervention consisted of immediate CP (early plasma group) versus no CP unless developing prespecified criteria of deterioration (deferred plasma group). Additional standard treatment was allowed in both arms. The primary outcome was a composite of mechanical ventilation, hospitalization for >14 days, or death. The key secondary outcomes included time to respiratory failure, days of mechanical ventilation, hospital length of stay, mortality at 30 days, and SARS-CoV-2 real-time PCR clearance rate. Of 58 randomized patients (mean age, 65.8 years; 50% male), 57 (98.3%) completed the trial. A total of 13 (43.3%) participants from the deferred group received plasma based on clinical aggravation. We failed to find benefit in the primary outcome (32.1% versus 33.3%, odds ratio [OR] 0.95, 95% CI 0.32-2.84, p > 0.999) in the early versus deferred CP group. The in-hospital mortality rate was 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17 p = 0.246), mechanical ventilation 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17, p = 0.246), and prolonged hospitalization 21.4% versus 30.0% (OR 0.64, 95% CI, 0.19-2.10, p = 0.554) in the early versus deferred CP group, respectively. The viral clearance rate on day 3 (26% versus 8%, p = 0.204) and day 7 (38% versus 19%, p = 0.374) did not differ between groups. Two patients experienced serious adverse events within 6 hours after plasma transfusion. The main limitation of this study is the lack of statistical power to detect a smaller but clinically relevant therapeutic effect of CP, as well as not having confirmed neutralizing antibodies in donor before plasma infusion.", "Conclusions", "In the present study, we failed to find evidence of benefit in mortality, length of hospitalization, or mechanical ventilation requirement by immediate addition of CP therapy in the early stages of COVID-19 compared to its use only in case of patient deterioration.
  • Thumbnail Image
    Item
    Prevalencia de pacientes con alto riesgo de caídas en un servicio médico-quirúrgico de un hospital universitario
    (2018) Aliaga, Braulio; Molina, Natalia; Noguera, Matías; Espinoza, Paula; Sánchez, Sebastián; Lara Hernández, Bárbara Alejandra; Carrasco Gorman, Marcela; Eymin Lago, Gonzalo